Altimmune, Inc. 10-Q filing
Filed 2026-05-13 · Report date 2026-03-31 · 2026
Filing metadata
- Accession number
- 0001326190-26-000040
- Form type
- 10-Q
- CIK
- 0001326190
- Primary document
- https://www.sec.gov/Archives/edgar/data/1326190/000132619026000040/alt-20260331x10q.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Altimmune, Inc..
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $5,000 | - | - |
| Operating Income | $-24.2M | - | - |
| Net Income | $-22.6M | - | - |
| Eps Basic | -0.18 | - | - |
| Eps Diluted | -0.18 | - | - |
| Cash And Equivalents | $97.6M | - | - |
| Total Assets | $335.6M | - | - |
| Total Liabilities | $51.6M | - | - |
| Shareholders Equity | $284.0M | - | - |
| Operating Cash Flow | $-20.9M | - | - |
| Capital Expenditures | $21,000 | - | - |